Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.
Akihiro YoshimuraMano HorinakaTakeshi YaoiHisako OnoKyoko ItohTadaaki YamadaTakayama KoichiToshiyuki SakaiPublished in: British journal of cancer (2024)
These results demonstrate that the epithelial-mesenchymal transition status may be a promising biomarker for the efficacy of combination therapy with avutometinib and defactinib in KRAS-mutated NSCLC.